10-((2-Hydroxybenzoyl)amino)decanoate sodium | 264602-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 10-((2-Hydroxybenzoyl)amino)decanoate sodium
• 英文别名: sodium;10-[(2-hydroxybenzoyl)amino]decanoate
• CAS: 264602-55-3
• 化学式: C17H24NNaO4
• 分子量: 329.4
• InChiKey: XUHVCHNJCBBXMP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.0
• 重原子数：
  23
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  89.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Formulations for oral administration of active agents
  申请人：Entera Bio Ltd.

  公开号：US10583177B2

  公开（公告）日：2020-03-10

  A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.

  本文公开了一种用于口服给药的药物组合物，它包含一种治疗活性剂、SNAC 和至少一种抗酸化合物。本文还公开了一种用于口服治疗活性剂的药物组合物单位剂型，该单位剂型包括：由治疗活性剂和 SNAC（8-N-(2-羟基苯甲酰基)氨基辛二酸钠）组成的核心；以及由至少一种保护剂组成的外层，该保护剂选自由抗酸剂化合物和蛋白酶抑制剂组成的组。本文进一步公开了利用上述药物组合物的方法和用途，以及通过口服联合给药至少一种抗酸剂组合物和包含治疗活性剂和SNAC的组合物的方法和用途，用于治疗可通过口服治疗活性剂治疗的病症。
• METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
  申请人：Oramed Ltd.

  公开号：EP2331072A1

  公开（公告）日：2011-06-15
• SOLID PHARMACEUTICAL COMPOSITION WITH ENHANCERS AND METHODS OF PREPARING THEREOF
  申请人：Merrion Research III Limited

  公开号：EP2536397A1

  公开（公告）日：2012-12-26
• TREATMENT OF OSTEOPOROSIS
  申请人：Entera Bio Ltd.

  公开号：EP3256114A1

  公开（公告）日：2017-12-20
• TREATMENT OF BONE FRACTURES AND DEFECTS
  申请人：Entera Bio Ltd.

  公开号：EP3256152A1

  公开（公告）日：2017-12-20